[1]马寄晓,叶大铸.奥曲肽及其类似物用于肿瘤治疗的进展[J].国际放射医学核医学杂志,2005,29(2):79-84.
　MA Ji-xiao,YE Da-zhu.Advances in tumor treatment with labeled somatostatin analogues[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):79-84.
点击复制

奥曲肽及其类似物用于肿瘤治疗的进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
29
期数:
2005年第2期
页码:
79-84
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Advances in tumor treatment with labeled somatostatin analogues
作者:
马寄晓1;  叶大铸2
1. 上海交通大学附属第六人民医院核医学科;
2. Memorial Sloan-Kettering Cancer Center; New York 10021; USA
Author(s):
MA Ji-xiao1;  YE Da-zhu2
1. Department of Nuclear Medicine, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong Uiversity, Shanghai 200233, China;
2. Memorial Sloan-Kettering Cancer Center, New York 10021, USA
关键词:
生长抑素; 奥曲肽; 分化型甲状腺癌; Hurthle细胞甲状腺癌; 甲状腺髓样癌; 胃肠胰神经内分泌肿瘤; 小细胞癌; 嗜铬细胞瘤
Keywords:
somatostatin; octreotide; differentiated thyroid cancer; Hurthle cell thyroid cancer; medullary thyroid cancer; gastro-entero-pancreatic tumor; small cell cancer; pheochromocytoma
分类号:
R817.5
摘要:
简单综述90Y-奥曲肽、177Lu-奥曲肽在肿瘤治疗中的应用价值。对奥曲肽治疗的原理、在肿瘤及正常组织中的分布、对肾脏功能的影响和保护剂的应用进行介绍,主要治疗的病种包括不摄取131I的分化型甲状腺癌转移灶、Hurthle细胞甲状腺癌、甲状腺髓样癌、来自胃肠胰的神经内分泌肿瘤、小细胞癌、嗜铬细胞瘤等。对应用适合的剂量和未来新的可能用于临床治疗的放射肽和发展方向加以综述。
Abstract:
The values of 90Y-octreotide and 177Lu-octreotate in tumor treatment were briefly reviewed.The rationale of clinincal applications, the distribution of radiopeptide in tumor and nomal tissues and appli-cation of renal protective agents were reviewed as well. Tumor with potential therapeutic responses are many such as non-iodide avid cancer of thyroid gland, Hurthle cell thyroid cancer, medullary thyroid cancer, neuroendo-gastro-entero-pancreatic(GEP)tumor, small cell l cancer, carcinoid tumors and pheochromocytoma. The current state of clinical use of radiopeptide for therapy of tumors, the development of new compounds and future development, the dosage of radiopeptide for tumor treatment with well tolerated and remarkable clinical benefit were presented.

参考文献/References:

1 Boerman O C, Oyen W J G, Corstens F H M. Between the scylla and charybdis of peptide radionuclide therapy:hitting the tumor and saving the kidney[J]. Eur J Nucl Med, 2001, 28:1447-1449.
2 Forssell-Aronsson E, Bernhardt P, Nilsson O, et al. Biodistribution data from 100 patients iv. injected with 111In-DTPA-D-pheloctreotide[J]. Acta Oncol, 2004, 43(5):436-442.
3 Bushnell D, Menda Y, O’Dorisio T, et al. Effect of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-octreotide (SMT487[Octreo TherTM])treatment[J]. Cancer Biother Radiopharm,2004, 19(1):35-41.
4 Pauwels S, Barone R, Walrand S, et al. Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs[J]. J Nucl Med, 2005, 46(1 suppl):92S-98S.
5 Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy:Yttrium-90-DOTATOC internal radiotherapy[J]. Am J kidney Dis, 2001,37(4):847-851.
6 Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion, a phase Ⅰ study[J]. Eur J Nucl Med Mol Imaging, 2003,30(2):207-216.
7 Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotidc by a combination of lysine and arginine[J]. Eur J Nucl Med Mol Imaging, 2003, 30(1):9-15.
8 Barone R, Pauwels S, De Camps J, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogs[J]. Nephrol Dial Transplant, 2004, 19(9):2275-2281.
9 Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC:relevence of kidney volume and dose rate in finding a dose-effect relationship[J]. J Nucl Med, 2005, 46(lsuppl):99s-106s.
10 Gabriel M, Froehlich F, Decristoforo C, et al. EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole body scan[J]. Eur J Nucl Med Mol Imaging, 2004, 31(3):330-341.
11 Giammarile F, Houzard C, Bournaud C, et al. Diagnostic management of suspected metastatic thyroid carcinoma:clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine Scans[J]. Eur J Endocrinol, 2004, 150(3):277-283.
12 Stokkel M P, Verkooijen R B, Smit J W. Indium-111 octretide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer:diagnostic and prognostic value[J]. EurJ Nucl Med Mol Imaging, 2004, 31(7):950-957.
13 Stokkel MP, Rcigman HI, Verkooijen RB, et al. Indiun-111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I- 131[J]. J Cancer Res Clin Oncol, 2003, 129(5):287-294.
14 Kostoglou-Athanassiou I, Pappas A, Gogou L, et al. Scintigraphy with 111In-octreotide and 201Tl in a Hurthle cell thyroid carcinoma without detectable radio-iodine uptake. Report of a case and review of the literature[J]. Horm Res, 2003, 60(4):205-208.
15 Tounissen J J, Kwekkeboom D J, Kooij P P, et al. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid cancer[J]. J Nucl Med, 2005, 46(1 suppl):107s-114s.
16 Rufini V, Salvatori M, Garganese M C, et al. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma[J]. Rays,2000, 25(2):273-282.
17 Papotti M, Kumar U, Volante M, et al. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid[J]. Clin Endocsinol, 2001, 54(5):641-649.
18 Bodei L, Haudkiewicz-Junak D, Grana C, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas[J]. Cancer Biother Radiophasm, 2004, 19(1):65-71.
19 Behe M, Behr T M. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies[J]. Biopolymers, 2002, 66(6):399-418.
20 Vainas I, Koussis CH, Pazaitou-Panayiotou K, et al. Somatastatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medulary thyroid carcinoma[J]. J Exp Clin Cancer Res, 2004, 23(4):549-559.
21 Saga T, Tamaki N, Itoi K, et al. Phase Ⅲ additional clinical study of 111In-pentetrootide (MP-1727):diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptor[J].Kaku Iguku, 2003, 40(2):185-203.
22 Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment[J]. Neuroendocrinology, 2004, 80(suppl 1):51-56.
23 Gibril F, Jensen R T. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroentero-pancreatic endocrine tumors[J].Dig Liver Dis, 2004, 36(suppl 1):S106-S120.
24 Virgolini I, Traub T, Novotny C, et al. Experience with indium-111and yttrium-90-1abeled somatostat in analogs[J]. Curr Pharm Des,2002, 8(20):1781-1807.
25 Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs[J]. J Nucl Med, 2005, 46:62S-66S.
26 Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma:subeellular expression pattern and functional relevance for octrootide scintigraphy[J]. J Clin Endocrin Metab, 2003, 88(11):5150-5157.
27 Pless M, Waldherr C, Maecke H, et al. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium labelled somatostatin analogue:a pilot trial[J]. Lung Cancer, 2004,45(3):365-371.
28 Schmitt A, Bernhardt P, Nilsson O, et al. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model[J]. J Nucl Med, 2004, 45(9):1542-1548.
29 Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin[J]. Clin Nucl Med, 2002, 27(1):11-17.
30 Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate[J]. J Nucl Med, 2005, 46(Suppl 1):83S-91S.
31 Waldherr C, Pless M, Maecke H.R, et al. Tumor response and clinical benefit in neuroendocrin tumors after 7.4Bq 90Y-DOTATOC[J]. J Nucl Med, 2002, 43(5):610-616.
32 Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic(GEP) tumours with the novel radiolabelled somatostatin analogue[177Lu-DOTA(0),Tyrs]octreotate[J]. Eur J Nucl Med Mol Imaging, 2003, 30(3):417-422.
33 de Jong M, Breeman WA, Valkema R, et al. Combination radionuelide therapy using 177Lu- and 90Y-labeled somatostatin analogs[J]. J Nucl Med, 2005, 46(1 suppl):13S-17S.
34 Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future[J]. J Nucl Med, 2005, 46(1 suppl):67S-75S.
35 Gotthardt M, Boermann OC, BehrTM, et al. Development and clinical application of peptide-based radiopharmaceuticals[J]. Curr Pharm Des, 2004, 10(24):2951-2963.

相似文献/References:

[1]夏伟,吕中伟,王国玉,等.99Tcm标记depreotide及与肺腺癌A549细胞亲和性研究[J].国际放射医学核医学杂志,2010,34(4):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
　XIA Wei,LÜ,Zhong-wei,et al.Experimental studies of depreotide labeled with 99Tcm and the affinity with human lung adenocarcinoma cell line A549[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
[2]高玉婷,王自正.生长抑素类似物介导靶向显像及治疗的研究现状和进展[J].国际放射医学核医学杂志,2009,33(6):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
　GAO Yu-ting,WANG Zi-zheng.The development of somatostatin analogues mediated tumor targeting and therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
[3]侯仁花,吕中伟.生长抑素受体显像剂99mTc-depreotide的研究进展[J].国际放射医学核医学杂志,2008,32(1):15.
　HOU Ren-hua,LÜ,Zhong-wei.The progress of a new somatostatin receptor agent 99mTc-depreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):15.
[4]苏燕,王峰,王自正,等.131Ⅰ-Tyr-octreotide的标记方法学及其生物学分布的研究[J].国际放射医学核医学杂志,2007,31(5):257.
　SU Yan,WANG Feng,WANG Zi-zheng,et al.abeling mothod and biodistribution of 131Ⅰ-Tyr-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):257.
[5]王秀娟,李险峰.生长抑素受体肿瘤显像的临床应用及研究进展[J].国际放射医学核医学杂志,2006,30(4):217.
　WANG Xiu-juan,LI Xian-feng.Clinical application and progress of somatostatin receptor imaging in diagnosis of cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):217.
[6]郭睿,晋建华.99mTc-depreotide生长抑素受体显像的临床应用研究[J].国际放射医学核医学杂志,2007,31(3):154.
　GUO Rui,JIN Jian-hua.The clinical application and study of 99mTc-depreotide somatostatin receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):154.
[7]宋进华,王自正,周云,等.188Re-奥曲肽在荷瘤裸鼠体内分布的实验研究[J].国际放射医学核医学杂志,2006,30(1):14.
　SONG Jin-hua,WANG Zi-zheng,ZHOU Yun,et al.Experimental study on biodistribution of 188Re-octreotide in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):14.
[8]罗全勇.多肽受体靶向放射治疗:现状与进展[J].国际放射医学核医学杂志,2005,29(2):74.
　LUO Quan-yong.Peptide receptor radionuclide therapy: current status and future directions[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):74.
[9]周玉凤.放射性核素标记小分子多肽治疗肿瘤的研究进展[J].国际放射医学核医学杂志,2005,29(3):105.
　ZHOU Yu-feng.The recent development of receptor targeting therapy for tumors with radiopeptides[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):105.
[10]段炼,李险峰.甲状腺相关眼病与生长抑素受体显像[J].国际放射医学核医学杂志,2005,29(3):108.
　DUAN Lian,LI Xian-feng.Thyroid associated ophthalmopathy and somatostatin receptor scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):108.
[11]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
　LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[12]王佳琼,王自正,姚薇萱,等.乳腺肿瘤生长抑素受体表达与生长抑素受体显像[J].国际放射医学核医学杂志,2006,30(1):17.
　WANG Jia-qiong,WANG Zi-zheng,YAO Wei-xuan,et al.Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):17.
[13]叶大铸,马寄晓.奥曲肽及其类似物用于肿瘤诊断的进展[J].国际放射医学核医学杂志,2003,27(3):97.
　YE Da-zhu,MA Ji-xiao.Advances in tumor diagnosis with labeled somatostatin analogues[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(2):97.
[14]章斌.188Re直接标记octreotide的方法学[J].国际放射医学核医学杂志,2002,26(5):220.
　ZHANG Bin.Investigations of directly labelling octreotide with 188Re[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(2):220.

备注/Memo

备注/Memo:
收稿日期:2005-01-15。
更新日期/Last Update: 1900-01-01